Valink Therapeutics
BostonFounded 202115+ employeesPrivate
$11.9M raisedSeed· last: seed (Oct 2025)· 4 rounds
Backed by(11 investors)
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
